AVEO ONCOLOGY and Astellas Pharma Inc. will end an agreement to develop the investigational cancer drug tivozanib by Aug. 11.
JIM ALLISON has been awarded the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.
THE AMERICAN CANCER SOCIETY added five new officers to its 2014 national volunteer board of directors. Pamela Meyerhoffer, a 40-year volunteer with the society, will chair the new board.
JOHN WALTER, president and CEO of The Leukemia & Lymphoma Society since 2008, has stepped down.
FRASER SYMMANS was named director of the CALGB Alliance Translational Research Program. He will oversee the activities of all scientific and administrative committees.
WAUN KI HONG announced his plans to retire as head of the MD Anderson Cancer Center Division of Cancer Medicine effective this summer after 30 years at that institution. Hong is 71.
AMGEN and MERCK announced an agreement to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a phase Ib/II study in mid- to late-stage melanoma.
HEALTH CANADA approved the Aptima HPV 16 18/45 genotype assay for use on the Panther system, both developed by Hologic Inc. The assay is the only approved test for genotyping human papillomavirus types 16, 18 and/or 45 in Canada.
DEFINIENS and Clarient Diagnostic Services Inc. signed an agreement to extend the use of Definiens' automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer.
THE UNIVERSITY OF PITTSBURGH selected GenomOncology's GenomAnalytics platform and services to explore and mine the data in The Cancer Genome Atlas.
